CareRx Sees Growth with Increased Bed Count and Improved Financial Results

CareRx ( (TSE:CRRX) ) has provided an announcement.

CareRx Corporation reported its financial results for the second quarter of 2025, highlighting a growth in bed count to 91,062, which is expected to drive future growth. The company’s revenue for the quarter was $91.4 million, showing a slight increase from the previous quarter. Adjusted EBITDA also improved to $8.0 million due to increased bed servicing and cost-saving initiatives. Net income rose to $0.6 million, a significant improvement from a net loss in the same quarter of the previous year. The Ontario Ministry of Health’s decision to pause changes to long-term care pharmacy funding, which would have reduced professional fees, is expected to positively impact CareRx’s financial stability.

The most recent analyst rating on (TSE:CRRX) stock is a Hold with a C$2.25 price target. To see the full list of analyst forecasts on CareRx stock, see the TSE:CRRX Stock Forecast page.

Spark’s Take on TSE:CRRX Stock

According to Spark, TipRanks’ AI Analyst, TSE:CRRX is a Neutral.

CareRx’s overall stock score reflects a blend of strong cash management and positive corporate events offset by poor valuation metrics and challenges in achieving consistent profitability. The company’s recent return to profitability and strategic initiatives provide a positive outlook, but financial performance and valuation concerns remain significant risks.

To see Spark’s full report on TSE:CRRX stock, click here.

More about CareRx

CareRx Corporation is Canada’s leading provider of pharmacy services, specializing in serving seniors living and other congregate care communities. The company focuses on delivering high-quality care while efficiently scaling its operations.

Average Trading Volume: 44,952

Technical Sentiment Signal: Buy

Current Market Cap: C$182M

See more data about CRRX stock on TipRanks’ Stock Analysis page.